In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $0.17 down -11.58% from its previous closing price of $0.19. In other words, the price has decreased by -$11.58 from its previous closing price. On the day, 4.53 million shares were traded. BTAI stock price reached its highest trading level at $0.1948 during the session, while it also had its lowest trading level at $0.16.
Ratios:
For a deeper understanding of BioXcel Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.87.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 16 ’24 when O’Neill Vincent sold 165 shares for $0.35 per share. The transaction valued at 58 led to the insider holds 19,957 shares of the business.
Mehta Vimal sold 3,117 shares of BTAI for $1,131 on Dec 16 ’24. The CEO and President now owns 59,605 shares after completing the transaction at $0.36 per share. On Dec 16 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 577 shares for $0.36 each. As a result, the insider received 207 and left with 20,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 511798 and an Enterprise Value of 68555056. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.59. Its current Enterprise Value per Revenue stands at 28.529 whereas that against EBITDA is -0.657.
Stock Price History:
The Beta on a monthly basis for BTAI is 0.82, which has changed by -0.9153846 over the last 52 weeks, in comparison to a change of 0.19995654 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $3.96, while it has fallen to a 52-week low of $0.18. The 50-Day Moving Average of the stock is -56.04%, while the 200-Day Moving Average is calculated to be -82.12%.
Shares Statistics:
For the past three months, BTAI has traded an average of 1.81M shares per day and 184841 over the past ten days. A total of 42.46M shares are outstanding, with a floating share count of 41.29M. Insiders hold about 16.74% of the company’s shares, while institutions hold 6.36% stake in the company. Shares short for BTAI as of 1730332800 were 347081 with a Short Ratio of 0.88, compared to 1727654400 on 516384. Therefore, it implies a Short% of Shares Outstanding of 347081 and a Short% of Float of 1.09.
Earnings Estimates
The stock of BioXcel Therapeutics Inc (BTAI) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$3.04, with high estimates of -$2.72 and low estimates of -$3.36.
Analysts are recommending an EPS of between -$23.68 and -$27.2 for the fiscal current year, implying an average EPS of -$25.33. EPS for the following year is -$13.49, with 3.0 analysts recommending between -$7.84 and -$23.04.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $718.26k this quarter.It ranges from a high estimate of $2.34M to a low estimate of $150k. As of the current estimate, BioXcel Therapeutics Inc’s year-ago sales were $376kFor the next quarter, 5 analysts are estimating revenue of $350k. There is a high estimate of $400k for the next quarter, whereas the lowest estimate is $300k.
A total of 5 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $5.37M, while the lowest revenue estimate was $2.05M, resulting in an average revenue estimate of $2.84M. In the same quarter a year ago, actual revenue was $1.38MBased on 5 analysts’ estimates, the company’s revenue will be $5.52M in the next fiscal year. The high estimate is $14.17M and the low estimate is $1.5M.
